Kairos Pharma, Ltd. (KAPA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 16, 2025, reports the closing of a private placement offering (PIPE) by Kairos Pharma, Ltd. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Los Angeles, California. The filing details the entry into material definitive agreements and the unregistered sale of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $3,497,500 raised from the sale of 2,500,000 Pre-Funded Units.
- Unit Price: $1.399 per Pre-Funded Unit.
- Additional Capital: $2,500 payable upon full exercise of Pre-Funded Warrants ($0.001 per share).
- Placement Agent Fees: 8% of gross proceeds paid in cash (including a 1% expense fee) plus warrants to purchase 175,000 shares.
- Debt and Liquidity: The filing does not provide specific balance sheet data regarding total debt, cash on hand, or liquidity ratios outside of the transaction proceeds.
Material Changes and Transaction Structure
The Company closed the sale of 2,500,000 units to an accredited investor. Each unit consists of:
- One Pre-Funded Warrant exercisable for one share of common stock at $0.001.
- One Common Warrant exercisable for 1.5 shares of common stock at $1.40 per share.
Amendments to Terms: Prior to closing, the Securities Purchase Agreement was amended to:
- Require shareholder approval for issuances exceeding 19.99% of outstanding common stock.
- Make Common Warrants immediately exercisable.
- Reduce the Common Warrant exercise period from 5.5 years to five years.
Boustead Securities, LLC and D. Boral Capital LLC acted as co-placement agents, splitting the cash and warrant compensation equally.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures regarding the unregistered nature of the securities. The securities were issued in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. The Company is obligated to file a resale registration statement within 15 days of closing and seek effectiveness within 30 days thereafter.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding post-closing to assess the dilution impact of the 2,500,000 Pre-Funded Units and the 1.5x warrant coverage.
- Confirm the status of the shareholder approval requirement for issuances exceeding 19.99% of common stock.
- Review the full text of the Amended and Restated Securities Purchase Agreement (Exhibit 10.1) for covenants and redemption rights.
- Monitor the filing of the resale registration statement required within 15 days of the January 16, 2025 closing.
- Assess the Company's cash runway given the $3.5 million raised, as no other liquidity metrics are provided in this filing.